Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Purchased by Fisher Asset Management LLC

Fisher Asset Management LLC increased its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 89.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 68,446 shares of the company’s stock after purchasing an additional 32,238 shares during the quarter. Fisher Asset Management LLC owned 0.08% of Day One Biopharmaceuticals worth $999,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DAWN. First Turn Management LLC acquired a new stake in Day One Biopharmaceuticals during the 4th quarter worth approximately $24,834,000. TimesSquare Capital Management LLC grew its position in Day One Biopharmaceuticals by 45.8% in the fourth quarter. TimesSquare Capital Management LLC now owns 1,666,065 shares of the company’s stock valued at $24,325,000 after acquiring an additional 523,455 shares in the last quarter. Braidwell LP grew its position in Day One Biopharmaceuticals by 13.5% in the fourth quarter. Braidwell LP now owns 4,215,573 shares of the company’s stock valued at $61,547,000 after acquiring an additional 500,000 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Day One Biopharmaceuticals by 28.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock valued at $30,935,000 after acquiring an additional 472,654 shares in the last quarter. Finally, Superstring Capital Management LP acquired a new stake in Day One Biopharmaceuticals in the fourth quarter valued at approximately $5,543,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on DAWN shares. The Goldman Sachs Group lowered their price objective on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Tuesday, May 7th. Piper Sandler reaffirmed an “overweight” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. Oppenheimer reissued a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. Finally, JPMorgan Chase & Co. raised their price target on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a research report on Monday, April 22nd. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Day One Biopharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.67.

Insider Buying and Selling at Day One Biopharmaceuticals

In related news, General Counsel Adam Dubow sold 3,253 shares of Day One Biopharmaceuticals stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $16.08, for a total transaction of $52,308.24. Following the sale, the general counsel now directly owns 21,731 shares in the company, valued at $349,434.48. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, General Counsel Adam Dubow sold 3,253 shares of Day One Biopharmaceuticals stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $16.08, for a total transaction of $52,308.24. Following the sale, the general counsel now directly owns 21,731 shares in the company, valued at $349,434.48. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Jeremy Bender sold 7,873 shares of Day One Biopharmaceuticals stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $16.08, for a total value of $126,597.84. Following the transaction, the chief executive officer now directly owns 654,728 shares in the company, valued at $10,528,026.24. The disclosure for this sale can be found here. Over the last three months, insiders have sold 185,534 shares of company stock worth $3,236,030. 8.40% of the stock is owned by insiders.

Day One Biopharmaceuticals Price Performance

Shares of DAWN opened at $13.68 on Friday. The business’s fifty day moving average price is $14.68 and its 200 day moving average price is $14.70. Day One Biopharmaceuticals, Inc. has a 12-month low of $9.67 and a 12-month high of $18.07. The stock has a market capitalization of $1.20 billion, a PE ratio of -5.45 and a beta of -1.53.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Monday, May 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.05). As a group, research analysts anticipate that Day One Biopharmaceuticals, Inc. will post -2.69 earnings per share for the current fiscal year.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.